Gapping up
In reaction to strong earnings/guidance updates:
- NVTR +20.9%, CERS +11.5%, NBY +9.1%, KSS +8.5%, NURO +7.5%, NVRO +7.2%, MZOR +6.3%, VRAY +5.6%, CROX +4.4%, BOOT +3.5%, NBIX +3.4%, CHS +3.2%, PLCE +2.9%, LULU +2.9%, DLA +2.7%, MDXG +1.6%, LIVE +1.1%, RXN +1%, CHEF +1%, .
M&A news:
- ABLX +84% (receives proposal from Novo Nordisk (NVO) for upto €30.50 per share in cash), GLUU +1.6% (divestiture of Moscow studio along with the sale of several titles developed by that location), MNK +0.9% (signs distribution agreement for Piclidenoson in 3 European countries with Gebro Holdings), .
Other news:
- CANF +17.9% (signs distribution agreement for Piclidenoson in 3 European countries with Gebro Holdings), VUZI +14.4% (continued strength), MTNB +11.6% (NIH have relayed to the Company positive data from a third patient enrolled in the collaborative Phase 2a clinical study of Matinas' lead anti-infective product candidate MAT2203), ALDR +10% (announces Eptinezumab significantly reduces migraine risk meets primary and all key secondary endpoints in pivotal PROMISE 2 Phase 3 trail), ADAP +8.4% (announces data from its studies of SPEAR T-cells targeting MAGE-A10), NVRO +7.2% (receives FDA approval for Senza II spinal cord stimulation system delivering HF10 therapy), TGTX +4.3% (TG Therapeutics and Jiangsu Hengrui Medicine announce global license agreement for development and commercialization of Novel BTK inhibitor program for the treatment of hematologic malignancies), GLPG +3.9% (reports positive topline results with GLPG1972), ACRS +3.5% (announces its two Phase 2 clinical trials (WART-202 and WART-203) of A-101 45% topical solution met all primary and secondary endpoints of each trial), NCTY +3.1% (entered into a definitive agreement with Red Ace Ltd for the issuance and sale of 3,571,429 ordinary shares of the Company), ALNY +3% (Alnylam Pharma and Sanofi (SNY) enter into strategic restructuring of RNAi Therapeutics rare disease alliance), FLXN +3% (announces initial findings from its ongoing Phase 3b), DVAX +2.7% (estimates that cash, cash equivalents and marketable securities were approximately $191.9 million as of December 31, 2017), EMES +2.4% (enters into refinancing transactions), CHRS +1.7% (granted type 2 FDA meeting), TRVN +1.5% (discloses that the FDA indicated on Jan 5 that the Prescription Drug User Fee Act review date for the OLINVO NDA is November 2 2018), BOMN +1.4% (invested $10 mln equity in national homebuilder Dream Finders Holdings), .
Analyst comments:
- FLIR +3% (upgraded to Buy from Hold at SunTrust)
- UTX +1.8% (upgraded to Buy from Neutral at Goldman)
- BBT +1.4% (upgraded to Equal-Weight from Underweight at Morgan Stanley)
- CAT +1.4% (upgraded to Overweight from Neutral at JP Morgan)
- AMAT +1.3% (upgraded to Strong Buy from Buy at Needham)
- EA +1.3% (upgraded to Outperform from Market Perform at BMO Capital Markets)
- SPLK +1.1% (upgraded to Overweight from Equal Weight at Barclays)
- RHP +1% (upgraded to Buy from Underperform at BofA/Merrill)
